Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilenia Valentino

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Antioxidants (Basel, Switzerland)|January 28, 2026
OPA1 as a Cancer Target: Molecular Mechanisms, Structural Insights, and Strategies for Drug DevelopmentAntonio Curcio, Ludovica Ganino, Ilenia Valentino, et al.
Pharmaceuticals (Basel, Switzerland)|September 27, 2025
Discovery of a Promising Hydroxyamino-Piperidine HDAC6 Inhibitor via Integrated Virtual Screening and Experimental Validation in Multiple MyelomaFederica Chiera, Antonio Curcio, Roberta Rocca, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|December 8, 2025
Dysregulated mitochondrial dynamics in cancer: Unlocking new strategies to combat drug resistanceTeresa Rossi, Roberta Torcasio, Ludovica Ganino, et al.
Cancers|March 28, 2026
Targeting Mitochondrial Vulnerabilities in Chronic Myeloid Leukemia: From Pathobiology to Novel Therapeutic OpportunitiesFrancesco Caprino, Ilenia Valentino, Antonella Bruzzese, et al.
Pharmaceuticals (Basel, Switzerland)|December 23, 2023
New Insights for Polyphenolic Compounds as Naturally Inspired Proteasome InhibitorsEmanuela Marchese, Maria Eugenia Gallo Cantafio, Francesca Alessandra Ambrosio, et al.
Pharmaceuticals (Basel, Switzerland)|May 27, 2026
Coumarin- and Dipicolylamine-Terpenoid Hybrids as Selective Carbonic Anhydrases IX and XII Inhibitors: Mechanistic Insights and Selective Anti-Cancer PotentialVenkatesan Saravanan, Andrea Angeli, Francesco Melfi, et al.
Journal of Translational Medicine|August 15, 2025
Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclaxIlenia Valentino, Maria Eugenia Gallo Cantafio, Roberta Torcasio, et al.
Antioxidants (Basel, Switzerland)|November 27, 2024
Hit Identification and Functional Validation of Novel Dual Inhibitors of HDAC8 and Tubulin Identified by Combining Docking and Molecular Dynamics SimulationsAntonio Curcio, Roberta Rocca, Federica Chiera, et al.
International Journal of Biological Macromolecules|May 21, 2026
Inhibition of the oncogenic GTPase dynamin-related protein 1 (DRP1) by the FDA-approved drug fosaprepitant: In silico, biophysical, and in vitro characterization of its anti-myeloma activityEmanuela Marchese, Pierpaolo Murfone, Ilenia Valentino, et al.
Journal of Translational Medicine|February 27, 2024
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activityRoberta Torcasio, Maria Eugenia Gallo Cantafio, Claudia Veneziano, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Antioxidants (Basel, Switzerland)|January 28, 2026
OPA1 as a Cancer Target: Molecular Mechanisms, Structural Insights, and Strategies for Drug DevelopmentAntonio Curcio, Ludovica Ganino, Ilenia Valentino, et al.
Pharmaceuticals (Basel, Switzerland)|September 27, 2025
Discovery of a Promising Hydroxyamino-Piperidine HDAC6 Inhibitor via Integrated Virtual Screening and Experimental Validation in Multiple MyelomaFederica Chiera, Antonio Curcio, Roberta Rocca, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|December 8, 2025
Dysregulated mitochondrial dynamics in cancer: Unlocking new strategies to combat drug resistanceTeresa Rossi, Roberta Torcasio, Ludovica Ganino, et al.
Cancers|March 28, 2026
Targeting Mitochondrial Vulnerabilities in Chronic Myeloid Leukemia: From Pathobiology to Novel Therapeutic OpportunitiesFrancesco Caprino, Ilenia Valentino, Antonella Bruzzese, et al.
Pharmaceuticals (Basel, Switzerland)|December 23, 2023
New Insights for Polyphenolic Compounds as Naturally Inspired Proteasome InhibitorsEmanuela Marchese, Maria Eugenia Gallo Cantafio, Francesca Alessandra Ambrosio, et al.
Pharmaceuticals (Basel, Switzerland)|May 27, 2026
Coumarin- and Dipicolylamine-Terpenoid Hybrids as Selective Carbonic Anhydrases IX and XII Inhibitors: Mechanistic Insights and Selective Anti-Cancer PotentialVenkatesan Saravanan, Andrea Angeli, Francesco Melfi, et al.
Journal of Translational Medicine|August 15, 2025
Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclaxIlenia Valentino, Maria Eugenia Gallo Cantafio, Roberta Torcasio, et al.
Antioxidants (Basel, Switzerland)|November 27, 2024
Hit Identification and Functional Validation of Novel Dual Inhibitors of HDAC8 and Tubulin Identified by Combining Docking and Molecular Dynamics SimulationsAntonio Curcio, Roberta Rocca, Federica Chiera, et al.
International Journal of Biological Macromolecules|May 21, 2026
Inhibition of the oncogenic GTPase dynamin-related protein 1 (DRP1) by the FDA-approved drug fosaprepitant: In silico, biophysical, and in vitro characterization of its anti-myeloma activityEmanuela Marchese, Pierpaolo Murfone, Ilenia Valentino, et al.
Journal of Translational Medicine|February 27, 2024
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activityRoberta Torcasio, Maria Eugenia Gallo Cantafio, Claudia Veneziano, et al.
Pageof 2